Oct 28, 2026 04:05PM
Aug 17, 2026 05:33PM
Aug 5, 2026 04:28PM
Jun 23, 2026 02:09PM
Jun 23, 2026 02:00PM
May 11, 2026 04:05PM
Mar 9, 2026 04:15PM Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Jan 12, 2026 10:14AM
Dec 8, 2025 08:32AM
Nov 7, 2025 09:00AM
Nov 7, 2025 09:00AM
Nov 6, 2025 04:14PM
Nov 6, 2025 01:55PM
Nov 6, 2025 01:54PM Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Aug 7, 2025 04:41PM
May 12, 2025 04:15PM
Mar 10, 2025 04:12PM
Dec 3, 2024 10:14AM
Aug 8, 2024 04:05PM
Jun 27, 2024 08:27AM
Jun 27, 2024 08:26AM Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
May 24, 2024 05:49AM
May 23, 2024 05:51PM
Mar 4, 2024 01:00AM
Jan 4, 2024 08:00AM
Dec 27, 2023 12:00PM
Dec 27, 2023 07:57AM
Dec 26, 2023 04:03PM Coherus (CHRS) Announces FDA Approval of UDENYCA ONBODY
Dec 7, 2023 05:55PM
Nov 28, 2023 11:17AM
Nov 28, 2023 11:16AM
Nov 6, 2023 04:07PM
Oct 27, 2023 03:10PM
Oct 27, 2023 03:07PM
Oct 5, 2023 08:53AM Coherus (CHRS) Announces Resubmission of BLA Supplement for UDENYCA ONBODY
Sep 27, 2023 09:10AM
Sep 25, 2023 08:32AM
Sep 8, 2023 09:05AM
Jul 20, 2023 04:04PM
Jun 16, 2023 07:05AM
Jun 1, 2023 08:35AM
Jun 1, 2023 08:33AM Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
Apr 27, 2023 08:05AM
Mar 6, 2023 04:01PM
Mar 6, 2023 08:01AM
Mar 6, 2023 08:00AM
Feb 15, 2023 08:26AM
Feb 15, 2023 08:25AM
Feb 13, 2023 08:25AM Coherus BioSciences (CHRS) Granted Permanent, Product-Specific Q-Code for CIMERLI
Feb 13, 2023 08:25AM

335,956 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All